Here are three things to know:
1. Histogenics’ restorative cell therapy platform is designed to enhance the autologous cartilage repair process to produce functional living cartilage at the time of treatment.
2. The company’s first RCT product candidate, NeoCart, is intended to rebuild a patient’s own knee cartilage and may delay or prevent osteoarthritis.
3. Adam Gridley serves as president and CEO of Histogenics. He has more than 20 years of experience in the medical device, biotechnology and pharmaceutical industries.
More articles on biologics:
Imagion Biosystems incorporates ‘printer & ink’ business model for medical imaging
SpinalCyte receives additional patents: 3 takeaways
3 things to know about Lattice Biologics’ CEO
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
